10-Q: Mountain Crest Acquisition Corp. V Reports Third Quarter 2024 Results and Provides Business Combination Update

Mountain Crest Acquisition Corp. V reported a net loss for the third quarter of 2024 and provided an update on its business combination agreement with CUBEBIO Co., Ltd.

Summary

• Mountain Crest Acquisition Corp. V, a blank check company, reported a net loss of $130,870 for the three months ended September 30, 2024, compared to a net loss of $1,932,911 for the same period in 2023.
• The company's general and administrative expenses were $202,182 for the quarter, significantly lower than the $1,988,611 reported in the same quarter of the previous year.
• Interest income from investments held in the Trust Account was $76,529 for the quarter, compared to $71,564 in the same period of 2023.
• For the nine months ended September 30, 2024, the company's net loss was $220,998, compared to a net loss of $2,182,359 for the same period in 2023.
• The company has extended the deadline to complete a business combination to November 16, 2025.
• The company entered into a business combination agreement with CUBEBIO Co., Ltd. on August 29, 2024.
• As of September 30, 2024, the company had $46,054 in cash held outside its Trust Account and $5,994,370 in investments held in the Trust Account.
• The company has been working to regain compliance with Nasdaq listing rules, and has received confirmation that it has regained compliance with the Listing Rule on October 30, 2024.

Sentiment

Score: 4

Explanation: The document contains both positive and negative elements. The company has made progress in securing a business combination and regaining Nasdaq compliance, but it continues to operate at a loss and faces risks related to its ability to complete the merger and maintain financial stability. The history of material weaknesses in internal controls is also a concern.

Positives

• The company significantly reduced its net loss in the third quarter of 2024 compared to the same period in 2023.
• General and administrative expenses were substantially lower in Q3 2024 compared to Q3 2023.
• The company has secured a business combination agreement with CUBEBIO Co., Ltd.
• The company has successfully extended the deadline to complete a business combination to November 16, 2025.
• The company has regained compliance with Nasdaq listing rules.

Negatives

• The company continues to operate at a loss, with a net loss of $130,870 for the third quarter of 2024.
• The company has incurred significant expenses related to its operations and pursuit of a business combination.
• The company has a history of material weaknesses in internal controls.

Risks

• The company may not be able to complete the proposed business combination with CUBEBIO Co., Ltd.
• The company's ability to continue as a going concern is dependent on completing a business combination by November 16, 2025.
• The company has a history of material weaknesses in internal controls, which could impact the reliability of financial reporting.
• The company may need to raise additional capital to complete the business combination or fund operations.
• The company is subject to risks associated with early-stage and emerging growth companies.
• The company is subject to the risk of the excise tax on stock redemptions.

Future Outlook

The company is focused on completing its business combination with CUBEBIO Co., Ltd. by the extended deadline of November 16, 2025. The company may need to raise additional capital to complete the business combination or fund operations.

Management Comments

• Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, raises substantial doubt about the Companys ability to continue as a going concern.
• Management intends to complete the proposed Business Combination before the mandatory liquidation date.

Industry Context

This announcement is typical for a special purpose acquisition company (SPAC) that is nearing the end of its lifespan and is actively pursuing a business combination. The extension of the deadline and the signing of a definitive agreement are common steps in the SPAC lifecycle.

Comparison to Industry Standards

• The financial results of Mountain Crest Acquisition Corp. V are typical for a SPAC in its pre-merger phase, with minimal operating revenue and reliance on interest income from its trust account.
• The company's efforts to regain compliance with Nasdaq listing rules are also common for SPACs that have experienced redemptions and market fluctuations.
• The extension of the business combination deadline is a common practice among SPACs that require more time to finalize a deal.
• The company's general and administrative expenses are relatively high compared to some other SPACs, but this can vary depending on the specific circumstances and activities of each company.
• The company's reliance on promissory notes from its sponsor for working capital is a common practice among SPACs.

Related Party Transactions

• The company has entered into several promissory note agreements with its sponsor.
• The company has an administrative support agreement with its sponsor.
• The company has converted promissory notes and vendor liabilities into shares of common stock with related parties.

Stakeholder Impact

• Shareholders are subject to the risk of potential losses if the business combination is not completed.
• Shareholders may experience dilution if additional shares are issued to fund the business combination.
• Employees may be impacted by the uncertainty surrounding the company's future.
• Creditors are subject to the risk of non-payment if the company is unable to complete the business combination.

Next Steps

• The company will seek to complete the business combination with CUBEBIO Co., Ltd.
• The company will continue to monitor its financial condition and seek additional financing if needed.
• The company will work to remediate the material weaknesses in internal controls.

Key Dates

Keywords

Business Combination, SPAC, CUBEBIO, Merger, Acquisition, Trust Account, Nasdaq, Financial Results, Redemption, Promissory Note